The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis

References

• Fritsch C, Neumann NJ, Ruzicka T, [Photodiagnostic tests. 3: Fluorescence diagnosis with delta-aminolevulinic acid-induced porphyrins (FDAP) in dermatology.] Hautarzt. 2000;51:528–543.
   Google Scholar
• Fritsch C, Lang K, Neuse W, Photodynamic diagnosis and therapy in dermatology. Skin Pharmacol Appl Skin Physiol. 1998;11:358–373.
   PubMedGoogle Scholar
• Boehncke WH, Konig K, Kaufmann R, Photodynamic therapy in psoriasis: Suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo. Arch Dermatol Res. 1994;286:300–303.
   PubMed Web of Science ®Google Scholar
• Collins P, Robinson DJ, Stringer MR, The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol. 1997;137:743–749.
   PubMed Web of Science ®Google Scholar
• Radakovic-Fijan S, Blecha-Thalhammer U, Schleyer V, Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br J Dermatol. 2005;152:279–283.
   PubMed Web of Science ®Google Scholar
• Robinson DJ, Collins P, Stringer MR, Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol. 1999;79:451–455.
   PubMed Web of Science ®Google Scholar
• Fransson J, Ros AM. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolaevulinic acid photodynamic therapy. Photodermatol Photoimmunol Photomed. 2005;21:326–332.
   PubMed Web of Science ®Google Scholar
• Stringer MR, Collins P, Robinson DJ, The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. J Invest Dermatol. 1996;107:76–81.
   PubMed Web of Science ®Google Scholar
• Smits T, Kleinpenning MM, van Erp PE, A placebo-controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. Br J Dermatol. 2006;155:429–436.
   PubMed Web of Science ®Google Scholar
• Fritsch C, Lehmann P, Stahl W, Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Br J Cancer. 1999;79:1603–1608.
   PubMed Web of Science ®Google Scholar
• Fritsch C, Ruzicka T. Fluorescence diagnosis and photodynamic therapy of skin diseases. Wien: Springer; 2003.
   Google Scholar
• Kleinpenning MM, Smits T, Ewalds E, Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: An immunohistochemical study. Br J Dermatol. 2006;155:539–545.
   PubMed Web of Science ®Google Scholar
• Gerritsen MJ, Rulo HF, Van Vlijmen-Willems I, Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: A cell biological study. Br J Dermatol. 1993;128:666–673.
   PubMedGoogle Scholar
• Presland RB, Coulombe PA, Eckert RL, Barrier function in transgenic mice overexpressing K16, involucrin, and filaggrin in the suprabasal epidermis. J Invest Dermatol. 2004;123:603–606.
   Google Scholar
• Takaishi M, Makino T, Morohashi M, Identification of human hornerin and its expression in regenerating and psoriatic skin. J Biol Chem. 2005;280:4696–4703.
   Google Scholar
• Gerritsen MJ, Boezeman JB, van Vlijmen-Willems IM, The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: A placebo-controlled, double-blind study. Br J Dermatol. 1994;131:57–63.
   PubMed Web of Science ®Google Scholar
• Gerritsen MJ, Elbers ME, de Jong EM, Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the active psoriatic plaque, in the uninvolved skin of psoriatic patients and in the normal healthy skin. J Dermatol Sci. 1997;14:179–188.
   PubMedGoogle Scholar
• Friedman SJ. Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol. 1987;123:1046–1052.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Staiano-Coico L, Cohen SR, Occlusive hydrocolloid dressings decrease keratinocyte population growth fraction and clinical scale and skin thickness in active psoriatic plaques. J Dermatol Sci. 1990;1:93–96.
   PubMedGoogle Scholar
• Gerritsen MJ, van Vlijmen-Willems IM, Chang A, The effect of a hydrocolloid occlusive dressing (DuoDERM E) on keratinization in psoriasis vulgaris. Acta Derm Venereol. 1994;74:483–484.
   Google Scholar
• Boehncke WH, Sterry W, Kaufmann R. Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet. 1994;343:801.
   Google Scholar
• Boehncke WH, Elshorst-Schmidt T, Kaufmann R. Systemic photodynamic therapy is a safe and effective treatment for psoriasis. Arch Dermatol. 2000;136:271–272.
   PubMed Web of Science ®Google Scholar